FOR IMMEDIATE RELEASE
New Published Study on a Polyphenol-Rich, Coffee Fruit Extract Beverage That Lowers Inflammatory Markers in People
MOMENCE,
IL – SoZo Global, LLC and FutureCeuticals, Inc. today announced the
publication of a pilotclinical study that reports SoZo’s exclusive
CoffeeBerry® - based functional beverage reduces inflammatorymarkers in
vivo.The SoZo® functional beverage contains a high ORAC,
polyphenol-rich, proprietary formula of fruit andvegetable extracts
featuring FutureCeuticals’ patented CoffeeBerry Brand Coffee Fruit
technology as the staringredient.
The double-blind,
placebo-controlled study—published online and in print in the latest
issue of the peerreviewedNutrition Journal—compared the effects of a
single dose of the SoZo beverage and a placebo onserum anti-inflammatory
and antioxidant markers in the blood of 31 healthy human subjects
randomized intothe two groups. At one hour after treatment, subjects in
the SoZo group showed an average 40% reduction inblood levels of
8-iso-PGF-alpha (isoprostanes), a vasoconstrictor implicated in many
inflammatory conditionsincluding obesity, diabetes, arthritis and
cardiovascular conditions. Reduction of isoprostanes levels
remainedevident for three hours following dosing. Administration of SoZo
also yielded a 39% reduction in AOPP(advanced oxidation protein
products), higher levels of which have been correlated with certain
cardiovascularconditions.
The study authors conclude that the
results justify further clinical investigations into the beneficial
effectsof the SoZo beverage on human health.
For more detailed information regarding the published study visit www.sozoclinicalstudy.com
